European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours

• Published in: Journal of neuroendocrinology Vol. 35; no. 12; pp. e13343 - n/a
• Main Authors: Kos‐Kudła, Beata, Castaño, Justo P., Denecke, Timm, Grande, Enrique, Kjaer, Andreas, Koumarianou, Anna, Mestier, Louis, Partelli, Stefano, Perren, Aurel, Stättner, Stefan, Valle, Juan W., Fazio, Nicola
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01-12-2023
• Subjects: diagnostics; guideline; Humans; Neuroendocrine tumors; Neuroendocrine Tumors - drug therapy; Neuroendocrine Tumors - therapy; neuroendocrine tumour; Pancreas; Pancreatic cancer; Pancreatic Neoplasms - diagnosis; Pancreatic Neoplasms - pathology; Pancreatic Neoplasms - therapy; pancreatic nonfunctioning neuroendocrine tumour; Societies; treatment; treatment; diagnostics; neuroendocrine tumour; pancreatic nonfunctioning neuroendocrine tumour; guideline
• ISSN: 0953-8194; 1365-2826
• DOI: 10.1111/jne.13343

This ENETS guidance paper for well‐differentiated nonfunctioning pancreatic neuroendocrine tumours (NF‐Pan‐NET) has been developed by a multidisciplinary working group, and provides up‐to‐date and practical advice on the management of these tumours. Using the extensive experience of centres treating patients with NF‐Pan‐NEN, the authors of this guidance paper discuss 10 troublesome questions in everyday clinical practice. Our many years of experience in this field are still being verified in the light of the results of new clinical, which set new ways of proceeding in NEN. The treatment of NF‐Pan‐NEN still requires a decision of a multidisciplinary team of specialists in the field of neuroendocrine neoplasms.
This ENETS guidance paper provides up‐to‐date practical advice on the NF‐Pan‐NET diagnosis and treatment. Management of NF‐Pan‐NET patients requires a NET‐dedicated MDT decision. ENETS Centres of Excellence should be strongly considered to be involved in the diagnostic‐therapeutic strategy of these patients. Further studies are needed to fulfil the unmet needs in this field focusing on prognostic molecular markers, dilemmas concerning the selection of a therapeutic approach as well as the sequence of their use to achieve success in the management of NF‐Pan‐NETs patients.